Skip to main content
Premium Trial:

Request an Annual Quote

Drug Abuse Institute Seeks PGx Proposals

Premium

The National Institute on Drug Abuse's medications development program is soliciting proposals on the pharmacogenetics of drug addiction.

"The genetics component of the clinical trials will focus on the identification of pharmacogenetic factors that predict patient response to medications and/or between-subject variations in pharmacokinetics, as well as the identification of biomarkers for addiction," NIDA said in a presolicitation issued last week.

Specifically, NIDA is interested in funding investigators that wish to "conduct the related DNA and RNA analyses on blood samples collected from … studies, to interpret the data, and to write high-quality reports and publications that summarize important findings."

NIDA is interested in seeing proposals for genotyping using Affymetrix GeneChip Mapping 500K array sets or equivalent platforms or proposals for expression analyses using Human Genome U-133 Plus 2.0 arrays or similar technology.

Winning proposals will be given a five-year contract in which NIDA will reimburse the cost of the PGx analysis.

NIDA said that the request for proposals will be available electronically around Jan. 28. Investigators interested in submitting a proposal should do so by March 14.

"NIDA will consider proposals submitted by any responsible offeror," the institute said.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.